Anti-atherosclerotic effects by PPARgamma and its ligands through the activation of reverse cholesterol transport system

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Peroxisome proliferator-activated receptor gamma (PPARgamma) belongs to a nuclear receptor superfamily which agonists were in clinical use for anti-diabetic therapy. Recent studies both in vivo and in vitro revealed that PPARgamma agonists have anti-atherosclerotic effects which is also demonstrated by a large clinical trial including PROactive study. One of the mechanisms for this effect is the activation of reverse cholesterol transport through the induction of ABCA1 transporter by PPARgamma agonists. The transporter exports cholesterol from macrophages migrating in the vasculature and inhibits the formation of foam cell which contains lipid droplet in the cytosol as cholesterol ester. Clinical application of PPARgamma agonists have beneficial effects by preventing the cardiovascular events in diabetic patients.

Original languageEnglish
Pages (from-to)217-223
Number of pages7
JournalNippon rinsho. Japanese journal of clinical medicine
Volume68
Issue number2
Publication statusPublished - 2010 Feb

Fingerprint

PPAR gamma
Cholesterol
Ligands
Foam Cells
Cholesterol Esters
Cytoplasmic and Nuclear Receptors
Cytosol
Macrophages
Clinical Trials
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{73021273972743429f11eb2922904057,
title = "Anti-atherosclerotic effects by PPARgamma and its ligands through the activation of reverse cholesterol transport system",
abstract = "Peroxisome proliferator-activated receptor gamma (PPARgamma) belongs to a nuclear receptor superfamily which agonists were in clinical use for anti-diabetic therapy. Recent studies both in vivo and in vitro revealed that PPARgamma agonists have anti-atherosclerotic effects which is also demonstrated by a large clinical trial including PROactive study. One of the mechanisms for this effect is the activation of reverse cholesterol transport through the induction of ABCA1 transporter by PPARgamma agonists. The transporter exports cholesterol from macrophages migrating in the vasculature and inhibits the formation of foam cell which contains lipid droplet in the cytosol as cholesterol ester. Clinical application of PPARgamma agonists have beneficial effects by preventing the cardiovascular events in diabetic patients.",
author = "Shu Wakino and Hiroshi Itoh",
year = "2010",
month = "2",
language = "English",
volume = "68",
pages = "217--223",
journal = "Nihon rinsho. Japanese journal of clinical medicine",
issn = "0047-1852",
publisher = "Nipponrinsho Co., Inc.",
number = "2",

}

TY - JOUR

T1 - Anti-atherosclerotic effects by PPARgamma and its ligands through the activation of reverse cholesterol transport system

AU - Wakino, Shu

AU - Itoh, Hiroshi

PY - 2010/2

Y1 - 2010/2

N2 - Peroxisome proliferator-activated receptor gamma (PPARgamma) belongs to a nuclear receptor superfamily which agonists were in clinical use for anti-diabetic therapy. Recent studies both in vivo and in vitro revealed that PPARgamma agonists have anti-atherosclerotic effects which is also demonstrated by a large clinical trial including PROactive study. One of the mechanisms for this effect is the activation of reverse cholesterol transport through the induction of ABCA1 transporter by PPARgamma agonists. The transporter exports cholesterol from macrophages migrating in the vasculature and inhibits the formation of foam cell which contains lipid droplet in the cytosol as cholesterol ester. Clinical application of PPARgamma agonists have beneficial effects by preventing the cardiovascular events in diabetic patients.

AB - Peroxisome proliferator-activated receptor gamma (PPARgamma) belongs to a nuclear receptor superfamily which agonists were in clinical use for anti-diabetic therapy. Recent studies both in vivo and in vitro revealed that PPARgamma agonists have anti-atherosclerotic effects which is also demonstrated by a large clinical trial including PROactive study. One of the mechanisms for this effect is the activation of reverse cholesterol transport through the induction of ABCA1 transporter by PPARgamma agonists. The transporter exports cholesterol from macrophages migrating in the vasculature and inhibits the formation of foam cell which contains lipid droplet in the cytosol as cholesterol ester. Clinical application of PPARgamma agonists have beneficial effects by preventing the cardiovascular events in diabetic patients.

UR - http://www.scopus.com/inward/record.url?scp=77949894146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949894146&partnerID=8YFLogxK

M3 - Article

C2 - 20158087

AN - SCOPUS:77949894146

VL - 68

SP - 217

EP - 223

JO - Nihon rinsho. Japanese journal of clinical medicine

JF - Nihon rinsho. Japanese journal of clinical medicine

SN - 0047-1852

IS - 2

ER -